Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite, President and CEO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 am ET in Boston, Massachusetts. The live audio webcast of the company’s presentation and subsequent replay may be accessed at http://wsw.com/webcast/cowen38/fldm. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650 243 6628 (office) [email protected]
